Best Pulmonology Companies in California, United States
The 94 best Pulmonology companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: ResMed.
Ranked: Best Pulmonology companies in California
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | ResMed Therapeutic devices to treat sleep apnea and respiratory disorders | $500M | 83 mo ago | 10,140 10,140 → 9,071 (-11%) · sector median +36% | 1989 | Michael Farrell Chief Executive Officer | 346 patents Advanced CPAP/BiPAP devices with smart humidification, mask fit analytics, and cloud data management | 1 internship · 1 launch · 1 award |
| 2 | Innoviva Manufacturer of respiratory-based generic drugs | $454M | 50 mo ago | 101 | 1996 | Pavel Raifeld CEO | — | 1 launch |
| 3 | ReCode Therapeutics Developer of precision medicines for treating lung related diseases 67Funding top 17%Talent top 28%Moat top 31%Market top 42% All 7 signals ▾Fundingtop 17% Talenttop 28% Moattop 31% Markettop 42% Newstop 45% Techtop 48% Globalbottom 39% Funding: Raised $342M across 7 rounds · 7 rounds over 7 yrs (1.0/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 67/100 | $342M | 8 mo ago | 105 | 2015 | Daniel Siegwart Co-Founder | — | — |
| 4 | Gossamer Bio Developer of small molecule-based therapies for treating immunological disorders, inflammation, and cancer | $330M | 35 mo ago | 102 102 → 137 (+34%) · sector median +36% | 2017 | Faheem Hasnain Founder | — | — |
| 5 | Endeavor Biomedicines Developer of therapeutics for the treatment of cancer and pulmonary diseases | $296M | 26 mo ago | 22 | 2018 | John Hood Founder and Executive Chairman | 29 patents Pulmonary fibrosis and lung function therapies using novel pharmaceutical compositions | — |
| 6 | Pulmonx Developer of smart devices for treating pulmonary diseases | $281M | 73 mo ago | 198 198 → 276 (+39%) · sector median +36% | 1998 | — | 313 patents Bronchoscopic devices and methods for lung diagnostics, imaging analysis, and volume reduction therapies | — |
| 7 | Vivus Developer of therapeutic solutions for obesity and sexual health | $253M | 157 mo ago | 59 | 1991 | Kent Blakely Founder | 254 patents Combination drug formulations and controlled-release delivery for obesity, pulmonary hypertension, and sleep apnea | — |
| 8 | Aradigm Developer of inhalable therapies for respiratory diseases | $199M | 106 mo ago | 23 | 1991 | — | 223 patents Liposomal inhalable antibiotics targeting pulmonary non‑tuberculous mycobacterial infections | — |
| 9 | 4D Molecular Therapeutics Developer of gene therapeutics for genetic disorders | $187M | 72 mo ago | 147 147 → 216 (+47%) · sector median +36% | 2013 | David Kirn Md Co-Founder & CEO | 246 patents Patents concentrated in chemistry & materials | — |
| 10 | aTyr Pharma Developer of protein biologics for treating multiple rare diseases | $172M | 105 mo ago | 65 65 → 75 (+15%) · sector median +36% | 2005 | Paul Schimmel Co-Founder | 534 patents Patents concentrated in chemistry & materials | — |
| 11 | Expedition Therapeutics Developer of treatments targeting inflammatory and respiratory diseases for patient care | $165M | 8 mo ago | — | 2024 | Yi Larson CEO & President | — | — |
| 12 | Noah Medical Developer of a robotic system designed for bronchoscopy procedures | $150M | 38 mo ago | 188 | 2018 | Jian Zhang Founder & CEO | 137 patents Robotic endoscopic navigation, instrumentation, and suturing for minimally invasive surgery | 1 launch · 2 awards |
| 13 | Aerin Medical Developer of therapeutic devices to improve nasal breathing | $144M | 18 mo ago | 66 66 → 156 (+136%) · sector median +36% | 2011 | Scott Wolf Co-Founder & CMO | 173 patents Therapies and devices for nasal/upper airway treatment and mucus reduction | 1 award |
| 14 | Endovascular Engineering Provider of mechanical thrombectomy technologies to treat venous thromboembolism 48Funding top 18%Growth top 30%Talent top 38%News top 47% All 8 signals ▾Fundingtop 18% Growthtop 30% Talenttop 38% Newstop 47% Moatbottom 48% Globalbottom 38% Marketbottom 36% Techbottom 30% Funding: Raised $122M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $122M | 2 mo ago | 19 | 2019 | Mike Rosenthal Co-Founder & Chief Operating Officer | — | 3 job openings · 1 internship |
| 15 | Aerovance Recombinant protein (IL-4 and IL-13 receptor antagonist) to treat asthma | $98M | 183 mo ago | — | 2004 | Mark L. Perry President and CEO | 70 patents IL-4/IL-13 antagonist biologics and dry‑powder peptide aerosol formulations for respiratory diseases | — |
| 16 | Rain Therapeutics Develoer of small molecules therapeutics for treating non-small cell lung cancer | $92M | 69 mo ago | 44 | 2017 | Robert Doebele Co-Founder | — | — |
| 17 | MediciNova Developer of small molecule for the treatment of acute exacerbations of asthma and COPD | $84M | 65 mo ago | 13 13 → 16 (+23%) · sector median +36% | 2000 | Yuichi Iwaki Founder & CEO | 289 patents Patents concentrated in health & consumer products | — |
| 18 | Elevation Pharmaceuticals Developer of aerosol drug products for COPD patients | $77M | 173 mo ago | 7 | 2007 | — | — | — |
| 19 | Uptake Medical Medical device company improving lives through vapor ablation for pulmonary disease | $72M | 125 mo ago | — | 2005 | — | — | — |
| 20 | Apieron Asthma monitoring device | $69M | 200 mo ago | 25 | 2001 | Holly McGarraugh CEO | 30 patents Breath analysis systems for medical diagnostics, focusing on gas detection and CO interference reduction. | — |
| 21 | APT Pharmaceuticals Development for drugs for treatment of lung diseases | $62M | 212 mo ago | — | 2005 | Stephen Dilly ex-CEO | — | — |
| 22 | Recludix Pharma Provider of the online platform for drug discovery and development | $60M | 55 mo ago | 33 33 → 54 (+64%) · sector median +36% | 2020 | Brian Hodous Co-Founder | — | — |
| 23 | Breathe Technologies Portable respiratory therapy systems | $60M | 97 mo ago | 97 | 2005 | — | 371 patents Non‑invasive mechanical ventilation hardware and integrated patient‑interface jet pump systems | — |
| 24 | Vascular Architects Developer of devices for the treatment of peripheral vascular disease and nonvascular obstructions | $55M | 261 mo ago | — | 1999 | — | 17 patents Peripheral vascular stents and drug‑eluting delivery systems for arterial interventions | — |
| 25 | CoTherix Inhaled therapeutics for the treatment of cardiopulmonary diseases. | $55M | 272 mo ago | 85 | 2000 | — | 17 patents Combination pulmonary hypertension therapies using inhaled vasodilator microparticles and metabolic syndrome drug combos | — |
| 26 | Inogen Provider of a portable oxygen concentrator for oxygen therapy | $52M | 170 mo ago | 1,000 1,000 → 845 (-16%) · sector median +36% | 2001 | — | 116 patents Patents concentrated in health & consumer products | — |
| 27 | Asthmatx SEO, web hosting, lighting, and hardware solutions for home and business | $50M | 229 mo ago | 40 | 2003 | — | 196 patents Energy-based devices for targeted airway and lung therapy. | — |
| 28 | PneumRx Medical solutions innovator dedicated to transforming lives through science | $50M | 185 mo ago | 7 | 2004 | — | 235 patents Minimally invasive pulmonary therapies, lung volume reduction implants, and device packaging solutions. | — |
| 29 | Broncus Developer of solutions for diagnosing and treating lung disease | $44M | 64 mo ago | 36 36 → 63 (+75%) · sector median +36% | 1998 | Hong Xu CEO | 2 patents Advanced medical imaging and therapy planning for radiation oncology and lung surgery | 1 partnership |
| 30 | Gala Therapeutics Developer of therapeutics for treating pulmonary disease including chronic bronchitis, COPD, and asthma | $43M | 79 mo ago | 24 | 2015 | — | — | 6 launchs |
| 31 | Reviva Pharmaceuticals Develops therapeutic drugs for treatment of central nervous system | $41M | 109 mo ago | 4 | 2006 | Laxminarayan Bhat President and CEO | 161 patents Liposomal drug delivery of Brilaroxazine for psoriasis and arylpiperazine therapies for pulmonary fibrosis | — |
| 32 | Spirosure Non-invasive breathalyzers for disease diagnosis and management | $41M | 101 mo ago | 12 | 2011 | Solomon Ssenyange Founder & Chairman | 29 patents Medical breath analysis and gas sensing devices for nitric oxide and respiratory monitoring | — |
| 33 | Attenua Developer of non-narcotic medicines for a chronic cough | $35M | 97 mo ago | — | 2015 | Jing Liang Co-Founder | 23 patents Pharmaceutical cough‑suppressant formulations and related active ingredient chemistries. | — |
| 34 | InterMune Therapies in pulmonology and orphan fibrotic diseases. | $27M | — | 359 | 1998 | Daniel Welch Chairman | 925 patents Anti-fibrotic pyridinone small molecules and pirfenidone oral formulations for treating fibrosis | — |
| 35 | Aluna Provider of smart devices for asthma management | $27M | 40 mo ago | 24 | 2020 | Inderjit Jutla Co-Founder & CTO | — | — |
| 36 | Corsair Phama Developer of drugs for the treatemnt of cardiac diseases | $23M | 33 mo ago | 5 | 2014 | Bobby Singh Chief Executive Officer | — | — |
| 37 | Telesair Provider of medical devices commercialization services | $23M | 4 mo ago | 24 | 2020 | Tyler Li Co-Founder | 56 patents Patents concentrated in health & consumer products | 1 award |
| 38 | AeroRx Developer of nebulized combination drug therapies for respiratory diseases | $21M | 8 mo ago | — | 2023 | Mei-chang Kuo Co-Founder | — | — |
| 39 | Aires Pharmaceuticals Therapies to treat pulmonary disorders | $20M | 187 mo ago | 2 | 2006 | Wendy Johnson Ex-President & CEO | — | — |
| 40 | GEn1E Developer of therapeutics for the treatment of inflammatory and rare diseases | $17M | 8 mo ago | 19 | 2018 | Ritu Lal Co-Founder & CEO | — | — |
| 41 | Adamis Pharmaceuticals Developer of therapeutics for treating respiratory disease and allergy | $16M | 76 mo ago | 15 | 2006 | — | 140 patents Injection devices and drug delivery formulations for emergency and therapeutic applications | — |
| 42 | TurnCare Technology solutions for critical care patient management, promoting health and safety | $16M | 70 mo ago | 34 | 2011 | Rafael Squitieri Co-Founder & CTO | 138 patents Therapeutic compression garments with inflatable perfusion and integrated power/monitoring systems | — |
| 43 | Rejuvenation Technologies Developer of nucleoside-modified TERT mRNA for antiaging | $15M | 13 mo ago | 12 | 2012 | Glenn Markov Co-Founder | — | — |
| 44 | Miist Therapeutics Developer of inhaled therapies for rapid symptom relief | $13M | 16 mo ago | — | 2022 | Dalton Signor Founder & CEO | — | — |
| 45 | Axikin US-based, clinical-stage biopharma developing chemokine receptor targeting small molecules for respiratory… | $12M | 129 mo ago | 2 | 2008 | Peter McWilliams CEO | — | — |
| 46 | Allux Medical Devices for treatment of hyper-reactive upper airway mucosa | $12M | 240 mo ago | — | 2004 | Erica Rogers President & CEO | — | — |
| 47 | LEADOPTIK Provider of AI-powered optical processors | $7M | 10 mo ago | 8 | 2020 | Jiang You Co-Founder & VP of Medical Imaging | 13 patents Miniaturized optical catheters and diffractive lenses for advanced endoscopic imaging and biopsy | — |
| 48 | Gyre Therapeutics Developer of anti-fibrotic therapeutics for a variety of chronic organ diseases | $5M | 31 mo ago | — | 2002 | Han Ying CEO | — | — |
| 49 | Halo Biosciences Developer of therapies by editing extracellular matrix | $5M | 14 mo ago | 12 | 2019 | Andy Wardle Co-Founder & Advisor | — | — |
| 50 | Makani Science Developer of a sensor-based device for monitoring respiratory rate | $125K | 14 mo ago | 6 | 2020 | Francis Duhay CEO | — | — |
Top 12 Pulmonology companies in California
#1
Series C · Menlo Park, California · founded 2019 · 19 employees$122.3Mraised▾
Provider of mechanical thrombectomy technologies to treat venous thromboembolism. It offers Hēlo Thrombectomy System designed to remove clots efficiently using a dual-action mechanism. It combines aspiration and mechanical clot disruption with a small profile catheter that expands for high-performance clot engagement.
- Apr 2026Series C$80M
- Feb 2025Series B$42M
- Apr 2022Seed—
- Sep 2021Grant (prize money)$298.2K
#2
Series B · Menlo Park, California · founded 2015 · 105 employees$342Mraised▾
Developer of precision medicines for treating lung-related diseases. The pipeline includes lead programs which includes RCT1100 an inhaled mRNA-based investigational therapy for primary ciliary dyskinesia caused by mutations in the DNAI1 gene and RCT2100 is an inhaled mRNA-based investigational therapy for cystic fibrosis. It has proprietary non-viral lipid nanoparticle platform that enables the delivery of a variety of payloads, and organ targeting of nucleic acid and protein payloads via both systemic and local delivery.
- Sep 2025Series B$29M
- Sep 2023Series B$50M
- Jan 2023Series B$10M
- Jun 2022Series B$120M
#3
Series A · San Diego, California · founded 2024$165Mraised▾
Developer of treatments targeting inflammatory and respiratory diseases for patient care. The company focuses on treatments addressing fundamental disease mechanisms for chronic obstructive pulmonary disease. Their therapy targets neutrophilic inflammation, a pathway driving tissue damage and lung function decline. The lead candidate is an oral DPP1 inhibitor being developed for COPD. It aims to deliver improvement for patients lacking disease-controlling options.
- Oct 2025Series A$165M
#4
Series A · Orange, California · founded 2020 · 24 employees$22.8Mraised▾
Provider of medical devices commercialization services
- Feb 2026Series A$3M
- Jan 2023Series A$22.8M
#5
Series A · Palo Alto, California · founded 2018 · 19 employees$17.2Mraised▾
Developer of therapeutics for the treatment of inflammatory and rare diseases. The company's platform is utilizing the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform to create novel therapies for rare and inflammatory diseases. The lead candidate molecule is "GEn-1124"- for lung chronic conditions and other candidate molecules are in the research and discovery phase.
- Oct 2025Series A$5.5M
- Dec 2022Series A$17M
- 2021Seed—
- Aug 2019Seed$125K
#6
Series E · Sunnyvale, California · founded 2011 · 66 employees$143.9Mraised▾
Developer of therapeutic devices to improve nasal breathing. It offers VivAer and RhinAer non‑invasive treatments that deliver tissue-sparing, temperature-controlled radiofrequency for nasal airway obstruction and chronic rhinitis.
- Dec 2024Series E$32.5M
- May 2022Series E$60M
- Aug 2020Series D$49.7M
- May 2019Conventional Debt$50M
#7
Series A · La Jolla, California · founded 2023$21Mraised▾
Developer of nebulized combination drug therapies for respiratory diseases. The company focuses on creating treatments for Chronic Obstructive Pulmonary Disease, particularly in older patients. Their approach involves combining multiple medications into a single nebulized therapy. This aims to improve treatment effectiveness and convenience for patients with respiratory conditions. The company targets the specific needs of the aging population facing respiratory challenges.
- Sep 2025Series A$21M
#8
Seed · Mountain View, California · founded 2012 · 12 employees$15.2Mraised▾
Rejuvenation Technologies is developing nucleoside-modified TERT mRNA. The nucleoside-modified TERT mRNA is used to extend the telomeres. It is based on the technology that telomere shortening affects cell function. The company has developed in-vivo based therapeutics (in-vivo testing phase) and cell therapies (out-licensing phase) for aging and treating fatal diseases.
- Apr 2025Grant (prize money)—
- Sep 2024Grant (prize money)$325K
- Aug 2024Grant (prize money)$1.1M
- Oct 2023Seed—
#9
Seed · Milpitas, California · founded 2020 · 8 employees$6.6Mraised▾
Provider of AI-powered optical processors. It develops an optical technology that uses machine learning for image analysis applications.
- Aug 2025Seed$4.6M
- May 2023Seed$6.6M
- 2020Seed—
#10
Series C · Solana Beach, California · founded 2018 · 22 employees$295.6Mraised▾
Developer of therapeutics for the treatment of cancer and pulmonary diseases. The company has developed a drug candidate ENV-101 which is a small-molecule inhibitor targeting the Hedgehog signaling pathway. It activates during embryonic development and helps in the treatment of the wound healing process in adults. The inhibitors provide solutions for the treatment of cancers such as basal cell carcinoma and acute myelogenous leukemia, pulmonary diseases such as lung fibrosis.
- Apr 2024Series C$132.6M
- Jan 2022Series B$101M
- Jan 2021Series A$62M
#11
Series A · Alameda, California · founded 2022$13.4Mraised▾
Developer of inhaled therapies for rapid symptom relief. The company utilizes a proprietary inhaler technology to deliver medication directly to the peripheral lung, enabling faster absorption into the bloodstream than traditional methods. This approach is being applied to develop treatments for various conditions, focusing on those with acute symptom onset where rapid action is critical. The platform features a small particle size for efficient delivery and a sterile, heat-free production process. Current development programs include treatments for smoking cessation and migraine.
- Feb 2025Series A$7M
- Aug 2024Series A$6.3M
- Oct 2022Seed$75K
#12
Public · San Diego, California · founded 2017 · 102 employees$330Mraised▾
Developer of small molecule-based therapies for treating immunological disorders, inflammation, and cancer. The company has developed a drug candidate GB001 (undisclosed target), used for treating inflammatory disorders. The company has also developed first-in-class HIF-1α stabilizers for the treatment of inflammatory bowel diseases.
- Jul 2023Post IPO$212.1M
- Jul 2022Post IPO$120M
- Jul 2018Series B$230M
- Jan 2018Seed$100M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Pulmonology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.